{"nctId":"NCT01004978","briefTitle":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","startDateStruct":{"date":"2009-10-28","type":"ACTUAL"},"conditions":["Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma"],"count":235,"armGroups":[{"label":"Arm I (sorafenib tosylate and TACE)","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Procedure: Computed Tomography","Drug: Doxorubicin Hydrochloride","Drug: Doxorubicin-Eluting Beads","Other: Laboratory Biomarker Analysis","Procedure: Magnetic Resonance Imaging","Drug: Mitomycin","Other: Pharmacological Study","Drug: Sorafenib Tosylate"]},{"label":"Arm II (placebo and TACE)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin","Procedure: Computed Tomography","Drug: Doxorubicin Hydrochloride","Drug: Doxorubicin-Eluting Beads","Other: Laboratory Biomarker Analysis","Procedure: Magnetic Resonance Imaging","Drug: Mitomycin","Other: Pharmacological Study","Other: Placebo Administration"]}],"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","CT","CT Scan","tomography"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Doxorubicin-Eluting Beads","otherNames":[]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"]},{"name":"Mitomycin","otherNames":["Ametycine","Jelmyto","MITO","Mito-C","Mito-Medac","Mitocin","Mitocin-C","Mitolem","Mitomycin C","Mitomycin-C","Mitomycin-X","Mitomycine C","Mitosol","Mitozytrex","Mutamycin","Mutamycine","NCI-C04706"]},{"name":"Pharmacological Study","otherNames":[]},{"name":"Placebo Administration","otherNames":[]},{"name":"Sorafenib Tosylate","otherNames":["BAY 43-9006 Tosylate","BAY 54-9085","Nexavar","sorafenib"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:\n\n  * Histologically confirmed\n  * Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion \\> 2 cm with early enhancement and delayed enhancement washout regardless of alpha-feto protein levels (AFP)\n  * AFP \\> 400 ng/mL AND evidence of at least one solid liver lesion \\> 2 cm regardless of specific imaging characteristics on CT or MRI\n* Patients must have hepatocellular carcinoma (HCC) limited to the liver; there must be no clinical or radiographic evidence of extrahepatic HCC\n* Portal lymphadenopathy IS permitted for patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) - as lymphadenopathy is commonly associated with hepatitis unrelated to malignancy\n* Staging CT of the chest and CT or MRI of the abdomen and pelvis must have been completed within 4 weeks of study registration\n* Patients must have measurable disease constituting \\< 50% of liver parenchyma within 4 weeks of registration\n* Patients may not have ascites detectable on physical examination\n* Patients must not be candidates for curative resection, orthotopic liver transplantation, or radiofrequency ablation (RFA)\n* Patients may have been treated with RFA in the past, but no sooner than 4 weeks before study registration\n* Patients may have undergone previously attempted curative liver resection\n* Patients may NOT have been previously treated with brachytherapy such as yttrium-90 microsphere\n* Patients may NOT have been previously treated with sorafenib, chemoembolization, or systemic chemotherapy including cytotoxic agents or molecularly targeted agents\n* Branch portal vein invasion by tumor is permitted but patients with main portal vein invasion by tumor are not eligible\n* Patients must have Child-Pugh score of A or B7 within 4 weeks prior to study registration\n* Serum total bilirubin =\\< 2.0 mg/dL\n* Alkaline phosphatase \\< 5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \\< 5 x ULN\n* Serum creatinine =\\< 1.5 mg/dL\n* Platelet count \\>= 50,000/mm\\^3\n* Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding\n* Patients must have no clinical signs of heart failure and meet New York Heart Association functional classification I or II defined as:\n\n  * Class I - patients with no limitation of activities; they suffer no symptoms from ordinary activities\n  * Class II - patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patients must have a life expectancy of at least 3 months\n* Patients must not be known to be human immunodeficiency virus (HIV) positive\n* Patients must not have other uncontrolled intercurrent illnesses excluding HBV or HCV, including, but not limited to: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/addictive disorders that would limit compliance with study requirements\n\n  * Uncontrolled hypertension is defined as optimally treated baseline blood pressure that exceeds 150/90 mm Hg\n* Patients must not be taking cytochrome P450 enzyme inducing drugs\n* Age \\>= 18 years\n* Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy\n* Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception\n* Patients must not have an allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication\n* Patient must be able to swallow pills, as study medications cannot be crushed","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"PFS is defined to be the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up will be censored at the date of last disease assessment without progression, unless death occurs within 4 months following the date last known progression-free, in which case the death will be counted as an event.\n\nProgression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) is defined as time from randomization to death from any cause, censoring cases who had not died at the date last known alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"19.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Among Patients With Extra-hepatic Progression","description":"PFS is defined to be the time from randomization to progression or death without evidence of progression.\n\nProgression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.\n\nFor patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. Patients with both intra- and extra-hepatic progression were considered as having extra-hepatic progression. This analysis was performed among patients with extra-hepatic progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression","description":"PFS is defined to be the time from randomization to progression or death without evidence of progression.\n\nProgression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.\n\nFor patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. This analysis was performed among patients with intra-hepatic progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pharmacogenetic and Pharmacokinetic Properties of Sorafenib Including Angiogenesis, Monooxygenases, Polymorphisms and Multidrug Resistance Mutation (MDR)","description":"This analysis will be performed across a few ECOG-ACRIN studies of sorafenib to evaluate the association between genotypes that are related with sorafenib activity and clinical outcomes.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Inter-reader Concordance for Response by EASL (European Association for the Study of the Liver) Criteria","description":"Response was determined using the European Association for the Study of the Liver (EASL) criteria, which was recommended as an alternative to RECIST for grading therapeutic response of advanced hepatocellular carcinoma (HCC). The EASL criteria use the longest dimension of enhancing tumor as the primary metric for gauging tumor response. The Kappa statistics will be applied to assess agreement between readers.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Association Between Objective Tumor Response by EASL Criteria and PFS as Well as OS","description":"PFS is defined to be the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up will be censored at the date of last disease assessment without progression, unless death occurs within 4 months following the date last known progression-free, in which case the death will be counted as an event.\n\nProgression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.\n\nOS is defined as time from randomization to death or date last known alive. Response is assessed at 4 and 8 months by EASL criteria.","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS.","description":"Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.\n\nFor patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic.\n\nOS is defined as the time from randomization to death or date last known alive.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":110},"commonTop":["Fatigue","Platelet count decreased","Anemia","Nausea","Abdominal pain"]}}}